Board and Management
Baruch Halpert
Yoram Azulai
Mr. Yoram Azulai serves as the Chief Financial officer of HBL. Prior to HBL, Mr. Azulai served as the CFO of Bio-light LTD. Prior to Bio-Light, Yoram held multiple financial managerial positions at Protalix LTD, D-Pharm, XTL, Pharmos and Brainstorm.
Mr. Azulai has over the last 20 years of experience dealing with business and finance aspects focused in the biotechnology arena, leading in IPO's, secondary public offering, private placement and M&A's transactions.
Mr. Azulai has an academic education in accounting and economic from The Open University of Raanana.
Michal Sapir
Michal Sapir brings more than 20 years of experience in corporate finance activities. Michal has worked as investment banker in local and international investment banks (Clal Manpikim, Broadview, AxcessNet) and as the head of strategy in ECI's CFO department. Michal has led dozens of M&A and fund raisings transactions in Israel, US and China. Ms. Sapir has been a board member in traded companies and is in the 2105's 500 recomended directors' list of the Israeli govermental authoritiy.
Ms. Sapir holds a BA in Political Sciences from the Hebrew University in Jerusalem, and an MBA from Stern School of Business at New York University (has specialized in finance).
At present Michal owns a business consulting company focusing on business development and strategic plans.
Doron Birger
Doron Birger is Director of IceCure,MCS and MEDIGUSpublicly traded on the TASE and chairman and Directorof variety of technologycompanies inthe fields of Medical Device,Internet,Digital Printing and Energy. Mr. Birger served as Chief Executive Officer of Elron Electronic Industries, Ltd., (Nasdaq ELRNF and TASE ), from August 2002 until April 2009and was chairman (2002-2007) and director of Given Imaging (Nasdaq :GIVN and TASE) until it was sold to Covidian in 2/2014. Prior to that, he held other executive positions at Elron, including President since 2001, Chief Financial Officer from 1994 to August 2002, and Corporate Secretary from 1994 to 2001. Until April 2009, Mr. Birger was a director or chairman of the board of directors of many privately held companies in the Elron group in the fields of medical devices, semiconductors and communication. From 1991 to 1994, Mr. Birger was Chief Financial Officer at North Hills Electronics Ltd., an advanced electronics company. From 1990 to 1991, Mr. Birger served as Chief Financial Officer of Middle-East Pipes Ltd., a manufacturer in the metal industry. From 1988 to 1990, Mr. Birger served as Chief Financial Officer of Maquette Ltd., a manufacturer and exporter of fashion items. From 1981 to 1988, Mr. Birger was Chief Financial Officer and director at Bateman Engineering Ltd. and I.D.C. Industrial Development Company Ltd. Mr. Birger is a director of the National Science & Technology Museum in Haifa, a director of the Israel Association of Electronics & Software Industries, a Director of "Young Entrepreneurs", a non-profit organization,a director at Sam Spiegel film school in Jerusalemand a director of "DVI" - the Dental Volunteers for Israel. Mr. Birger holds a B.A. and an M.A. in economics from the Hebrew University, Jerusalem.
Yigal Erlich
Yigal Erlich is the founder and managing partner of the Yozma Group a venture capital company in Israel. Mr. Erlich is considered as the founding father of the Israeli venture capital industry and one of the most prominent figures in the Israel high-tech arena. At the beginning of the 1990s, Mr. Erlich established Yozma, which was the first VC fund, sponsored by the government of Israel.
Following its privatization in 1997, Yozma joined forces with the Ofer Group to establish Yozma II and Yozma III.
The group managed over US $ 220 million and has invested in over 45 Portfolio companies.
Between 1984 and 1992, Mr. Erlich served as the Chief Scientist of Israel's Ministry of Industry and Trade. In 1991 Mr. Erlich started the Technology Incubator Program that led to the creation of 24 Incubation Centers throughout Israel, as well as international R&D agreements and other programs.
Mr. Erlich is the deputy chairman of the National R&D Council of Israel and former Chairman of Matimop, Israeli Industry Center for R&D, and the former Chairman of the Israel Venture Association. Mr. Erlich serves as a board member in several high tech companies as well as on Hadasit - the TTC of Hadasa hospital in Jerusalem. He is also a board member of the Russian Venture Company (RVC), which is a $1bil government Fund of Funds and the chairman of the Canadian international Private-Public-Forum.
Mr. Erlich holds B.Sc. and M.Sc. in Chemistry and an MBA from the Hebrew University of Jerusalem.
Yaakov Naparstek
Dr. Naparstek is a graduate of the Hadassah-Hebrew University Medical School in Jerusalem, Israel. He is Boards certified in Internal Medicine, Rheumatology and Clinical Immunology and Allergy. He has been a research fellow and a visiting Professor at the Weizmann Institute of Science, Rehovot, Tuft's University, Boston, The NIH, Bethesda and Stanford University, Stanford.
Dr. Naparstek is a Professor of Medicine in the Hebrew University, Jerusalem, and is the incumbent of the Leifferman Chair in Rheumatology. He was the Chairman of Medicine in the Hadassah University Hospital for 13 years as well as the Senior Deputy Director General for Research & Academic Affairs at the Hadassah University Hospital.
His main research interests are in the fields of autoimmunity, SLE, autoimmune arthritis and type 1 diabetes. In recent years his research group focused on the identification of target antigens in SLE and in autoimmune arthritis and diabetes and in the attempts to develop antigen-specific therapeutic modalities to those diseases.
In addtion to his academic and clinical activities, Dr. Naparstek has been involved in several medical humanitarian activities, such as the Israeli Medical Rescue Team for Campuchean refugeees in Cambodia, and served as a medical advisor to the Ministry of Health in British Guiana.
Dr. Naparstek is the Head of the Israelli Cell Therapy and Gene Therapy Committees of the Israeli MOH, and was a member of the National Committee for the Israeli "Health Basket", in addition to many other national and international committees. He is the founder and chief scientist of the Verto Medical and Protab Therapeutics biotechnological companies and a consultant and SAB member in other medical-biotechnology companies. Dr. Naparstek is the recipient of national and international awards, including the 2011 Elkeles Prize in Medicine and the author of more than 100 publications and chapters in books as well as many patents in the field of autoimmune inflammatory diseases.
Tamar Raz
Board member of Hadasit Bio
In previous position served as VP Marketing and Strategy of Ramot, the Technology Transfer Company of Tel Aviv University, and was responsible for the company strategic alliances and marketing activities.
Prior to joining Ramot in 2004, directed the establishment of Allergene, an Israeli start-up company that was founded as an incubator project, and served as its CEO.
Expertise include; commercialization of medical technologies from the academic/ laboratory bench to the industry in order to turn ideas into viable products and services for the benefit of humanity; establishment and management of corporate and academic relationships, animal models research, and pre-clinical development operations; raising funds including investment of venture capital, corporate collaborations, contractual research relationships and government grants.
Merav Kaye
Merav Kaye, board member of Hadassit Bio.
Merav has the breadth of experience in the realm of project management and business development as an experienced professional who worked for a large telecoms company in the past and as an investment manager in her current role within Consensus Business Group, a leading UK investment group.
Merav brings to the table the vast experience in mobilising companies from small Start Ups to IPO stage and beyond. Further experience is demonstrated by value floatation of invested companies.
As Merav sits several boards, she has the benefit of her pivotal position within a vital business stakeholder network.
Within her previous role, Merav managed in 012 Smile Ltd broad organisational projects focusing on benefits delivery to top management whilst practiving methodical and highly professional project management skills.
Elka Nir
Elka Nir has more than 25 years of extensive experience in senior executive positions in the area of Life Sciences. She brings significant experience in various executive leadership roles in large and small global companies as well as vast experience in investments, strategic alliances and chairperson / board member positions.
Since 2007, Elka is an active chairperson and board member of several public and private Life Sciences companies in various stages in Israel and globally (Among others: IceCure Medical and BSP Ltd. - traded in TASE). She also works closely with some investment parties.
Mrs. Nir is a board director of the Israeli High Tech Association (IATI) for the last 3 years.
Elka is also CEO of Carmel Ltd., the economic corporation of the Haifa University.
Elka also owns a business consulting company focusing on business strategy, business development, marketing and investments.
Until 2011, Elka has been Managing Director and Partner, in Giza Venture Capital, leading investments, IPO, M&As, strategic alliances and business successes in the portfolio companies. Formerly, Elka was COO & Director of Development at Biosense Webster, Johnson & Johnson. Prior to that, Elka served as VP, R&D and VP marketing at General Electric Medical Systems (GE), Israel.
Ms. Nir holds a B.Sc. in Computer Science, Technion-Israel's Institute of Technology, and Business Administration from the University of Haifa